(2) what assessment the Department has made of the impact on the NHS of the decision by Pfizer to sell its products through a single distribution channel from early 2007.
This is a commercial matter for Pfizer. Pfizer have assured the Department that it will make every effort to ensure that these new arrangements will not result in any disruptions in the supply of its United Kingdom-sourced branded medicines to national health service patients. The Department will monitor these new arrangements with a view to taking corrective action if appropriate.